Clinical Trial Update: Polydatin Injectable (HW6) for Shock Treatment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Polydatin Injectable (HW6) as a treatment for various forms of shock, including hemorrhagic, traumatic, and septic shock.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Shock
• Septic Shock
• Traumatic Shock

Drugs mentioned

• Polydatin Injectable (HW6) (polydatin)

Snippet

Sponsor: Neptunus Pharmaceuticals Inc. | Conditions: Shock, Hemorrhagic, Shock, Traumatic | Phase 2 | Status: UNKNOWN